Approval Package for:

APPLICATION NUMBER:

NDA 20-812/S-007

- *Trade Name:* Pediatric Advil Drops
- Generic Name: Ibuprofen
- *Sponsor:* Whitehall-Robins Healthcare
- Approval Date: September 7, 2000

Supplement Changes to the allergy alert wording in the labeling *Changes:*

APPLICATION NUMBER: NDA 20-812/S-007

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Labeling Review	X
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Other Reviews	
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Administrative/Correspondence Document(s)	X

APPLICATION NUMBER: NDA 20-812/S-007

APPROVAL LETTER

Public Health Service Food and Drug Administration Rockville MD 20857



NDA 20-812/S-007

Whitehall-Robins Healthcare Attention: Sharon Heddish Vice President, Regulatory Affairs - Worldwide Five Giralda Farms Madison, NJ 07940-0871

SEP 7 2000

Dear Ms. Heddish:

Please refer to your supplemental new drug application dated October 26, 1999, received October 28, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pediatric Advil (ibuprofen) Drops, 100 mg/2.5 mL.

This "Changes Being Effected" supplemental new drug application provides for revised labeling to implement the allergy alert statements required by our September 15, 1998 letter.

We have completed the review of this supplemental new drug application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the final printed labeling submitted on October 26, 1999. Accordingly, the supplemental new drug application is approved effective on the date of this letter.

We request that the labeling for this drug product be revised to comply with the requirements of 21 CFR 201.315 (sore throat warning) and 21 CFR 369.20 (general warning regarding accidental overdose by children) within 180 days or at the next printing, whichever comes first. In addition, please delete the period after the bulleted statement, "**Do not use**" on the bottle label.

We note that the labeling was not submitted in Drug Facts format consistent with the requirements of the March 17, 1999 FEDERAL REGISTER document "Over-the-Counter Human Drugs; Labeling Requirements; Final Rule" (64 FR 13254) (OTC labeling final rule), which has been incorporated into the regulations at 21 CFR 201.66. We remind you that the labeling of your product must be revised to reflect the Drug Facts format within the timeframes specified in the OTC labeling final rule.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we

La 9/7/00

NDA 20-812/S-007 Page 2

request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2 FDA 5600 Fishers Lane Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions regarding this application, please contact Thomas Parmelee, Pharm.D., Regulatory Project Manager, at 301-827-2271.

Sincerely,

Linda M. Katz, M.D., M.P.H.

Deputy Director Division of Over-the-Counter Drug Products Office of Drug Evaluation V Center for Drug Evaluation and Research NDA 20-812/S-007 Page 3

Albert al HFD-560/Rothselited/Lumpkins/Mason/Neuner/Roberts/Parmelee HFD-002/ORM (with labeling) HFD-105/ADRA (with labeling) HFD-40/DDMAC (with labeling) HFI-20/Press Office (with labeling) HFD-400/OPDRA (with labeling) HFD-613/OGD (with labeling) HFD-095/DDMS-IMT (with labeling) HFD-830/DNDC Division Director DISTRICT OFFICE

APPROVAL (AP)

APPLICATION NUMBER: NDA 20-812/S-007

LABELING

Labeling: ORIGINAL NDA No: Ro'd. 10-28-99 "oviewed by




Reviewed by:

20



Labeling: ORIGINAL NDA No: 20812 Ro'd.10-28-99

Reviewed by: _



Labeling: ORIBIANDA NDA No: 20812 Ro'd. 10-28-99

10

Reviewed by:


Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore
Bioeffore

a II heskabia ning se bollia sap is separated Battric Advis Drops PROFEN CRAL, SUSPENSION mp pare 2.5 mL (SUSPENSION Fover Reduce/Plain Reliever Lasts up to 8 Hours speciality. speciality.

Allergy Safet, buyelen my case a seven allergic casedow wich my positive thread subscript - tools with my positive thread subscript - tools with my and the seven is don allergic restion to say other gain allerer with dan allergic restion to say other gain allerer with dan allergic restion to say other gain allerer with dan allergic restion to say other gain aller dans allergic restion and all does 10 does 43 of ut. Cast backson to Book 43 of ut. Machan U. No 7900 Machan U. No 7900 Machan U. Safet Safet Safet Case Machan U. No 7900 Machan U. Safet Safet Case - Cast Safet Safet Safet Case - Case Safet Safet Safet Case - Case Safet Safet Safet Safet Safet Case - Case Safet Safet

Labeling: ORIBINAL NDA No: 20812 Bo'd. 10-28-99

Reviewed by:



Labeling: DRIBINAL NDA No: 20812 Ro'd. 10-28-99 Reviewed by:

Directions 1. Use this product only with chart provided. 2. Find right dose on chart below. It possible, use weight to dose. Otherwise, use up. 3. Measure dose with the dosing device provided. 4. Baneat dose wave 6-8 hours. If needed.


Sample - nor from RTAL SAFE De et als el Restabilitario (en barbit se be in sported Peoderarie C. ACAL Dispersion) 100 million (en barbit se bener Liste angeles: Doption Lister insporte) - reduces from the set book Area Diinteres many anne: - reduces from the set book Area Ditenteres many anne: Brook Area Ditenteres many anne: Brook Area Di-

D BROPS AND

A series of the the transmission of the transm

Labeling: ORIGINAL NDA No: 20812 Bo'd. 10-28-99

Reviewed by: ____



Labeling: ORIGINAL NDA No: 20812 Bo'd. 10-28-99 1.0 Reviewed by:

0172-20/2iA

12.7



APPLICATION NUMBER: NDA 20-812/S-007

LABELING REVIEW

DEC 1 5 1000

Labeling Review of NDA Supplement

NDA: 20-812/S-007

Submission Date:October 26, 1999Received:October 28, 1999Review Date:November 12, 1999

Applicant:

Whitehall-Robins Five Giralda Farms Madison, NJ 07940-0871 973-660-5753

Applicant's Representative: Sharon C. Heddish Vice President Regulatory Affairs – Worldwide

Drug:

Pediatric Advil Drops (Ibuprofen, 100 mg/2.5mL)

Pharmacologic Category:

Fever reducer/pain reliever

Submitted:

Special Supplement – CBE - Final printed Color labeling/diskette

Reviewer:

Stephanie A. Mason

The sponsor submitted 20 copies of final printed labeling for the following to be in compliance with the Agency's September 15, 1998 letter which provides for the required allergy alert and two additional warnings:

1. Pediatric Advil Drops (ibuprofen) Oral Suspension Grape/Fruit flavor 1/4 oz carton/label.

2. Pediatric Advil Drops (ibuprofen) Oral Suspension Grape/Fruit flavor ½ oz carton/label.

<u>Reviewer's comments</u>: Implementation of the required allergy alert, and two additional warnings is acceptable. For the bottle label, the sponsor should delete the period after the bulleted statement under **Do not use**, and include the sore throat warning in the labeling at the time of the next printing or within six months.

In addition, It is noted that the submitted labeling is outdated and does not include: (1) the required **Drug Facts** format per the final rule for OTC Labeling Requirements, (2) the amended warning regarding accidental overdose (§ 369.20), and (3) the required sore throat warning as stated in § 201.315.

An **Acknowledgement and Retain letter** should be sent to the sponsor. The sponsor should also be reminded of the deficiencies stated above.

Stephanie A. Mason

Stephanie A. Mason, IDS Reviewer

mit

Debbie L. Lumpkins, B.\$., Microbiologist Team Leader 3

APPLICATION NUMBER: NDA 20-812/S-007

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

ORIGINAL



Whitehall-Robins Five Giralda Farms Madison, NJ 07940-0871 Telephone (973) 660-5500 Website address: http://healthfront.com

NDA NO. 20812 REF NO. NDA SUPPL FOR 51

October 26, 1999

NDA 20-812 Pediatric Advil[®] Drops (ibuprofen 100 mg/2.5 mL)

Special Supplement - Changes Being Effected (Allergy Alert Warning)

Charles J. Ganley, M.D., Director Division of OTC Drug Products (**HFD-560**) Center for Drug Evaluation and Research Food and Drug Administration ATTN: Document Control Room 9201 Corporate Boulevard Rockville, MD 20857



Dear Dr. Ganley:

Reference is made to NDA 20-812 for Pediatric Advil[®] Drops (ibuprofen 100 mg/2.5 mL), sponsored by Whitehall-Robins Healthcare ("Whitehall-Robins"), a division of American Home Products Corporation. Reference is also made to your letter of September 15, 1998, regarding revised class-labeling for potential allergic reactions (attached).

This letter directed Whitehall-Robins to update the labeling of this product to comply with the required warning statements and submit final printed labeling (FPL) in the form of a SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED as described under 21 CFR 314.70(c). Enclosed herewith are 20 copies of the final printed labeling, ten of which are mounted on heavy weight paper for the products covered under this NDA. The following label components are enclosed:

Pediatric Advil[®] Drops Ibuprofen Oral Suspension Grape Flavor ¹/₄ oz Carton Pediatric Advil[®] Drops Ibuprofen Oral Suspension Grape Flavor ¹/₄ oz Label Pediatric Advil[®] Drops Ibuprofen Oral Suspension Grape Flavor ¹/₂ oz Carton Pediatric Advil[®] Drops Ibuprofen Oral Suspension Grape Flavor ¹/₂ oz Label Pediatric Advil[®] Drops Ibuprofen Oral Suspension Fruit Flavor ¹/₄ oz Carton Pediatric Advil[®] Drops Ibuprofen Oral Suspension Fruit Flavor ¹/₄ oz Label Pediatric Advil[®] Drops Ibuprofen Oral Suspension Fruit Flavor ¹/₂ oz Carton Pediatric Advil[®] Drops Ibuprofen Oral Suspension Fruit Flavor ¹/₂ oz Label

In addition an image of the labeling for the carton and label of the product is included on diskette in PDF format.


If you have any questions or comments regarding this submission, please contact the undersigned at (973) 660-5753 or Mary Davis at (973) 660-5825.

Sincerely,

WHITEHALL-ROBINS HEALTHCARE

Mary Howis

Sharon C. Heddish Vice President Regulatory Affairs - Worldwide



Public Health Service

Rockville MD 20857

Food and Drug Administration

NDA 20-589/NDA 20-812

Whitehall-Robins Healthcare Attention: Sharon Heddish Vice President, Regulatory Affairs Five Giralda Farms Madison, New Jersey 07940-0871

FD I F

5ept 15,1998 MHD

Dear Ms. Heddish:

Please refer to your new drug applications for Children's Advil (Grape) Suspension (ibuprofen), 100mg/5mL (NDA 20-589), and Pediatric Advil (Fruit) Drops (ibuprofen oral suspension), 100 mg/2.5 mL.

In an effort to improve the consistency of labeling for OTC drug products containing analgesic active ingredients, the Agency has reevaluated class labeling issues relating to these drug products. Included among the issues under evaluation were warnings relating to potential allergic reactions to these products, including those in aspirin-sensitive individuals.

We have completed our evaluation and have concluded that the following warning statements are required.

Allergy alert: ibuprofen may cause a severe allergic reaction which may include:• hives• facial swelling• asthma (wheezing)• shock

Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer.

Stop use and ask a doctor if an allergic reaction occurs. Seek medical help right away.

Of note, for pediatric drug products bearing allergy warning statements under the heading of "Aspirin Sensitive Children"; this heading will no longer be used. In addition, for products with drug fact format labeling, the last two warning statements must be placed under their respective subheadings as the first bulleted statement.

At this time, the Agency is requesting that the applicants of approved new drug applications for OTC internal analgesic drug products update the labeling of these products to comply with the labeling stated above. Please submit final printed labeling exactly as specified above in the form of "SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED" as described under 21 CFR 314.80(c). Please incorporate all previous revisions consistent with the most recently approved labeling. However, please do not include any other labeling changes in this supplemental new drug application. To facilitate review of your submission, please provide a highlighted or marked-up copy of the labeling that shows the changes being made.

NDAs 20-589/20-812

ł

The labeling changes must be implemented within 6 months or at the next printing, whichever comes first.

We remind you that you must comply with the requirements set forth under 21 CFR 314.80 and 31.81 for an approved NDA.

If you have any questions concerning this request, please contact Stephanie Mason, Acting Project Manager, at (301)-827-2275.

Sincerely yours,

D

Acting Director Division of OTC Drug Products Office of Drug Evaluation V Center for Drug Evaluation and Research

DEPARTMENT OF HEALTH & HUMAN SERVICES



Public Health Service

Food and Drug Administration Rockville MD 20857

NOV 1 1999

NDA 20-812/S-007

Whitehall Robins Healthcare 5 Giralda Farm Madison, NJ 17940

Attention: Sharon C. Heddish Vice President Regulatory Affairs-Worldwide

Dear Ms. Heddish:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Pediatric® Adivl Drop® (ibuprofen) 100mg/2.5ml Suspension

NDA Number: 20-812

Supplement Number: S-007

Date of Supplement: October 26, 1999

Date of Receipt: October 28, 1999

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on December 27, 1999 in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Food and Drug Administration Division of Over-the-Counter Drug Products, HFD-560 Office of Drug Evaluation V Center for Drug Evaluation and Research Attention: Document Control Room 5600 Fishers Lane Rockville, MD 20857

Sincerely,

len Men

Maria Rossana R. Cook, M.B.A. Chief, Project Management Staff Division of Over-the-Counter Drug Products, HFD-560 Office of Drug Evaluation V Center for Drug Evaluation and Research

NDA 20-812/S-007 Page 2

cc:

ſ

Original NDA 20-812/S-007 HFD-560/Div. Files HFD-560/CSO/K. Rothschild

SUPPLEMENT ACKNOWLEDGEMENT